In the first instance, we screened a large panel of coregulators (42) in the DEGs between TMPRSS2 fusion positive and negative prostate cancer in EA and AA patients in the TCGA prostate cancer cohort (TCGA-PRAD). This evidence concerns the gene TMPRSS2 and prostate carcinoma.